StockDuty ← Dashboard Aug 12, 2026 04:00 PM ET
CatalystFDA/Bio

Monopar Q2 Net Loss Widens; Rolling NDA Submission For ALXN1840 In Wilson Disease Underway

Monopar Q2 Net Loss Widens; Rolling NDA Submission For ALXN1840 In Wilson Disease Underway

What changed
Monopar Q2 Net Loss Widens; Rolling NDA Submission For ALXN1840 In Wilson Disease Underway
Why it matters
Monopar Q2 Net Loss Widens; Rolling NDA Submission For ALXN1840 In Wilson Disease Underway — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →